Weiner, Sophia
Sauer, Mathias
Visser, Pieter Jelle
Tijms, Betty M.
Vorontsov, Egor
Blennow, Kaj
Zetterberg, Henrik
Gobom, Johan
Funding for this research was provided by:
EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115372)
ZonMw (733050824736)
Swedish Research Council (2017-00915, 2018-02532)
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615)
Swedish Alzheimer Foundation (AF-930351)
Hjärnfonden (FO2017-0243, FO2019-0228)
ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236, JPND2021-00694)
National Institutes of Health (1R01AG068398-01)
Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)
Stiftelsen för Gamla Tjänarinnor
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer Drug Discovery Foundation (201809-2016862)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C)
Olav Thon Stiftelsen
Familjen Erling-Perssons Stiftelse
MIRIADE (860197)
UK Dementia Research Institute at UCL
Alzheimerfonden (AF-930934)
Gun och Bertil Stohnes Stiftelse (K8020065655)
Åhléns-stiftelsen (K8020071398)
University of Gothenburg
Article History
Received: 2 February 2022
Accepted: 11 April 2022
First Online: 14 May 2022
Declarations
:
: In clinical routine care, there may be left-over samples (blood, serum, plasma, urine, CSF or tissue etc.) after performance of all planned analyses, and the left-over samples will be destroyed. These samples can be de-identified so that they cannot be traced back to an individual patient. After such procedures, according to the Swedish Biobank law (Biobanks in Medical Care Act) and the Swedish ethical legislation (The Act concerning the Ethical Review of Research Involving Humans), these samples are no longer covered by the regulations. From an ethical perspective, such samples can thus be used in method development and comparisons or in validation studies.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.